Company: SPRB
Filing Date: 2025-04-15
Form Type: 8-K
Source: 0000950170-25-053944
Chunk: 1

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-04-15
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01 Regulation FD Disclosure.

On April 15, 2025, the Company presented a slide presentation with an overview of the Company’s new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B entitled “ Tralesinidase Alfa Enzyme Replacement Therapy for the Treatment of Sanfilippo Syndrome Type B (MPSIIIB)” (the “ Presentation”). A copy of the Presentation is furnished as Exhibit 99.2.

All of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.2) shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.